Automated interpretation enables efficient review, sign-off and rapid report delivery.
Integrated with ACMG/AMP guidelines for hereditary disease assessment and AMP/ASCO/CAP guidelines for somatic testing enabling universal and clear communication within the medical community.
Assess clinical actionability and pathogenicity with visibility to each piece of evidence linked to the quality-assured, source publication.
Access the industry’s largest, most up-to-date knowledgebase with nearly two decades of curation maintained in real-time by hundreds of MDs and PhDs.
Our team of experts are available to help effectively mange your NGS workflow, from planning to implementation.
We understand your data is precious; we provide peace of mind with comprehensive security combining network security, and system and software integrity.
Treatment and care decisions for cancer patients require extensive clinically-relevant information. QCI Interpret is continuously updated to provide the most current information to improve accuracy in NGS test interpretation and reporting.
As an undisputed industry leader and pioneer of molecular technologies, we combine decades of experience and global expertise to improve patient care for generations to come.
Clinical labs rolling out NGS-based cancer tests are confronted with two key challenges: the complexity of turning molecular profiling information into precise medical recommendations, and the time and effort it takes to generate actionable reports. QIAGEN Clinical Insight provides a rich and detailed, yet very clear and concise, report that suggests management and treatment options based on the patient’s gene variations that profile their disease and outline causal links. It is this kind of interpretation that gives clinical value to the data, and what enables the actual insights into a patient’s specific disease and treatment options.
Madhuri Hegde, PhD, FACMG
Professor of Human Genetics at the Emory University School of Medicine and Executive Director of the Emory Genetics Laboratory